Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Biotech Showcase 2018
16 slides from Kazia Therapeutics's conference presentation, Jan 9, 2018
Slide 1: Kazia Presentation to Biotech Showcase (ASX Release)
ASX RELEASE 10 January 2018 KAZIA PRESENTATION TO BIOTECH SHOWCASE Sydney, 10 January 2018 – Australian oncology-focused biotechnology company Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is pleased to release the presentation that CEO, Dr James Garner gave to Biotech Showcase in San Francisc
Slide 2: An emerging oncology developer with two clinical-stage programs
An emerging oncology developer with two clinical-stage programs Presentation to Biotech Showcase #BTS18 San Francisco, CA 9 January 2018 ASX: KZA | NASDAQ : KZIA | Twitter: @KaziaTx
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe- harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 4: Investment Highlights
Investment Highlights Oncology-focused biotech with two cancer therapies in clinical trials 1 - GDC-0084 entering phase II in glioblastoma multiforme - Cantrixil in phase I in ovarian cancer Well-differentiated assets, with lead program licensed from Genentech 2 - GDC-0084: brain-penetrant dual PI3K
Slide 5: Kazia is focused on development of high-potential novel therapies for poorly-served cancers
Kazia is focused on development of high-potential novel therapies for poorly-served cancers Identify Value Build Value Realise Value • Conduct focused clinical trials • Bring in under- • Identify optimal • Partner with big valued assets patient groups pharma for late- from other • Understand safety
Slide 6: A strong team brings international experience in big pharma and early-stage biotech
A strong team brings international experience in big pharma and early-stage biotech Board Scientific Advisory Board Iain Ross Professor Sir Murray Brennan Chairman Emeritus Chairman of Cancer Surgery at Memorial Sloan Kettering Executive and Board roles in pharma Hospital, New York and small biotech
Slide 7: Two clinical programs, with value-driving inflection points providing impactful newsflow during 2018
Two clinical programs, with value-driving inflection points providing impactful newsflow during 2018 GDC-0084 Brain-penetrant Read-out from PI3K inhibitor, Commencement dose developed to of phase II study optimisation Glioblastoma completion of in first-line GBM lead-in Multiforme phase I by compone
Slide 8: Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer
Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer Lung No clear 3-4 months 12-15 cause untreated months Breast or strong risk survival average 14 million factors survival with cancer cases treatment per annum Colon Any age, Five-year Prostate but most survival co
Slide 9: Current standard of care is essentially ineffective in up to 65% of GBM cases
Current standard of care is essentially ineffective in up to 65% of GBM cases Standard of Care Debulking surgery Radiotherapy + Temozolomide (‘Stupp where possible temozolomide maintenance therapy Regimen’) 6 weeks 4w 6 x 28-day cycles Temozolomide is clearly efficacious… …but only in ~35% of patien
Slide 10: The PI3K pathway is highly relevant to GBM, and GDC-0084 is well-differentiated within the class
The PI3K pathway is highly relevant to GBM, and GDC-0084 is well-differentiated within the class PI3K Activation in GBM PI3K Inhibitor Class is Diverse Differentiation Comparators Relevance PI3K pathway upregulated in ~90% of GBM cases GDC-0084 is a pan- Idelalisib (Gilead) – d a & b isoforms likely
Slide 11: The PI3K class has been further validated by approval of a second NCE in September 2017
The PI3K class has been further validated by approval of a second NCE in September 2017 PI3K class further validated by approval of Bayer’s AliqopaTM (copanlisib) for lymphoma in Sept 2017 • Two PI3K inhibitors now successfully brought to market – Zydelig (idelalisib) [Gilead] – Aliqopa (copanlisib)
Slide 12: Previous GBM failures are well understood, and can inform development of new therapies
Previous GBM failures are well understood, and can inform development of new therapies • Many small-molecule kinase inhibitors are not well brain-penetrant, and so reach Pharmacokinetic insufficient concentration at the tumour Failure • Many driver mutations for GBM, but few constitutive (e.g. EGFR
Slide 13: Genentech's phase I of GDC-0084 established dosing and showed favourable safety
Genentech’s phase I of GDC-0084 established dosing and showed favourable safety Safety Efficacy Signals • Phase I safety trial conducted by Genentech GDC-0084 • 47 patients enrolled with advanced 40% glioma (grade 3/4); average of Arresting Achieved three prior lines of therapy Tumour Growth ‘stable
Slide 14: GDC-0084 phase II study design in first-line setting is supported by clinician and regulatory feedback
GDC-0084 phase II study design in first-line setting is supported by clinician and regulatory feedback Maintenance Regulatory Strategy n = 114 temozolomide Debulking • Designed to provide robust Radiotherapy + surgery prior to R evidence of clinical efficacy, temozolomide study entry using an endpoi
Slide 15: Brain metastases from non-CNS tumors represent long-term market expansion potential
Brain metastases from non-CNS tumors represent long-term market expansion potential Overview Example: Breast Mets Next Steps • Estimated 100,000 - 200,000 • ~30-44% of metastatic HER2- • Use GBM as a ‘gateway cases/year in US positive metastatic breast indication’, with the potential cancer patients
Slide 16: www.kaziatherapeutics.com
www.kaziatherapeutics.com